Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


So Dam Won has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring the Therapeutic Potential of Nicotinamide‐N‐Methyltransferase in Clear Cell Renal Cell Carcinoma

    by Mingyu Kim, Hyung Ho Lee, So Dam Won, Yeon Sue Jang, Baek Gil Kim, Nam Hoon Cho, Young Deuk Choi, Hyun Ho Han, Jin Soo Chung

    Clear cell renal cell carcinoma (ccRCC) is a highly aggressive subtype of renal cancer, often associated with poor prognosis and high mortality rates. In this study, we identified Nicotinamide N-methyltransferase (NNMT) as a key gene involved in the pathogenesis of ccRCC through RNA sequencing analysis of tumor and normal tissues from 14 patients. NNMT was among the top five upregulated genes, and its high expression was significantly correlated with reduced overall, progression-free, and disease-specific survival in patients, as well as advanced pathological stages and higher histologic grades. Gene ontology (GO) enrichment analysis revealed NNMT's role in biological processes such as signal transduction and immune response. Immune cell infiltration analysis indicated that high NNMT expression was associated with increased infiltration of activated NK cells and macrophages, while low expression correlated with a higher presence of regulatory T cells. Functional studies using siRNA-mediated NNMT knockdown in ccRCC cell lines demonstrated a significant reduction in cell proliferation, with further analysis revealing altered gene expression profiles related to cell adhesion and calcium ion binding. These findings suggest that NNMT not only plays a pivotal role in ccRCC aggressiveness but also may serve as a valuable prognostic biomarker and a potential therapeutic target for improving clinical outcomes in patients with this malignancy.

  • Open Access

    Deciphering the Role of ERBB3 Isoforms in Renal Cell Carcinoma: A Comprehensive Genomic and Transcriptomic Analysis

    by Mingyu Kim, Hyung Ho Lee, So Dam Won, YeonSue Jang, Baek Gil Kim, Nam Hoon Cho, Young Deuk Choi, Jin Soo Chung, Hyun Ho Han

    ERBB3, a key member of the receptor tyrosine kinase family, is implicated in the progression and development of various human cancers, affecting cellular proliferation and survival. This study investigated the expression of ERBB3 isoforms in renal clear cell carcinoma (RCC), utilizing data from 538 patients from The Cancer Genome Atlas (TCGA) Firehose Legacy dataset. Employing the SUPPA2 tool, the activity of 10 ERBB3 isoforms was examined, revealing distinct expression patterns in RCC. Isoforms uc001sjg.3 and uc001sjh.3 were found to have reduced activity in tumor tissues, while uc010sqb.2 and uc001sjl.3 demonstrated increased activity. These variations in isoform expression correlate with patient survival and tumor aggressiveness, indicating their complex role in RCC. The study, further, utilizes CIBERSORTx to analyze the association between ERBB3 isoforms and immune cell profiles in the tumor microenvironment. Concurrently, Gene Set Enrichment Analysis (GSEA) was applied, establishing a strong link between elevated levels of ERBB3 isoforms and critical oncogenic pathways, including DNA repair and androgen response. RT-PCR analysis targeting the exon 21–23 and exon 23 regions of ERBB3 confirmed its heightened expression in tumor tissues, underscoring the significance of alternative splicing and exon utilization in cancer development. These findings elucidate the diverse impacts of ERBB3 isoforms on RCC, suggesting their potential as diagnostic markers and therapeutic targets. This study emphasizes the need for further exploration into the specific roles of these isoforms, which could inform more personalized and effective treatment modalities for renal clear cell carcinoma.

  • Open Access

    Co-Administration of Gagam-Sipjeondaebo-Tang and Ibuprofen Alleviates the Inflammatory Response in MPTP-Induced Parkinson’s Disease Mouse Model and RAW264.7 Macrophages

    by Sodam Won, Jade Heejae Ko, Hayoung Jeon, Seong-Sik Park, Seung-Nam Kim

    Parkinson’s disease (PD), a common neurodegenerative disease, is characterized by degeneration of dopaminergic neurons with neuroinflammation. Gagam-Sipjeondaebo-Tang (GST), a traditional herbal formula made of twelve medicinal herbs, is known to be effective in PD, and the use of ibuprofen has been associated with a lower risk of PD. The aim of this study was to evaluate whether the combined administration of GST and ibuprofen affects the inflammatory response of Parkinson’s disease. MPTP-induced parkinsonian mouse models were treated with GST or ibuprofen using oral gavage once a day for 5 days. The effects of GST were examined by measuring the TH level and expression of CD68 in the mice brain in addition to behavioral tests. The anti-inflammatory effect of GST on the LPS-treated RAW264.7 murine macrophages was examined using the NO assay. Inflammatory cytokines were analyzed using quantitative-PCR and flow cytometry. In the results, GST significantly improved the loss of dopaminergic neurons and alleviated PD-induced behavioral deficits. GST also decreased macrophage activation in the MPTP-induced PD mouse model. Interestingly, co-administration of GST and ibuprofen showed a synergistic effect in improving the loss of dopaminergic neurons and decreasing the activation of macrophages. Moreover, the NO level decreased in LPS-stimulated macrophages with this combined treatment. GST reduced iNOS, COX-2, IL-1β, and IL-6 levels, and co-administration with ibuprofen showed a synergistic effect. Furthermore, pretreatment of GST reduced the expression levels of MCP-1 and IL-12 p70 in LPS-stimulated RAW264.7 cells. These results can possibly suggest a future therapeutic approach for PD patients.